-
ARv7 and EPI-001 in Triple-Negative Breast Cancer
2026-10-08
A 2025 study examined androgen receptor (AR) and AR variant 7 (ARv7) as prognostic markers in triple-negative breast cancer and assessed how Enzalutamide and EPI-001 affected metastasis-related biology in MDA-MB-231 cells. The findings connect nuclear ARv7 with unfavorable clinical outcomes and support further investigation of N-terminal AR targeting, while remaining limited by cohort, model, and endpoint constraints.
-
JNJ-10198409: PDGFR Signaling and Evidence
2026-10-08
JNJ-10198409 is described by APExBIO as a platelet-derived growth factor receptor inhibitor for research on PDGF-linked kinase signaling, proliferation, angiogenesis, and fibrosis. This overview compares the supplier-reported pharmacology with findings from a 2025 Rice stripe virus study, emphasizing that the plant-virus work does not establish activity, relevance, or therapeutic potential for JNJ-10198409.
-
Cefodizime: Spectrum, Resistance, and Evidence
2026-10-07
Cefodizime is a third-generation cephalosporin antibiotic whose research value depends on interpreting spectrum, pharmacology, and resistance data together. This evidence-focused analysis connects its PBP activity with findings from a psychiatric-hospital surveillance study while clarifying what the data can—and cannot—support.
-
CTCF, Centromere Function, and Mitotic Fidelity
2026-10-07
The reference study uses rapid, inducible CTCF degradation to show that CTCF supports centromere mechanics, metaphase organization, accurate mitosis, and post-mitotic nuclear shape. Its evidence distinguishes CTCF loss from simple disruption of CENP-E recruitment and places CTCF closer to a centromere-maintenance role involving chromosome tension and cohesin-associated architecture.
-
MG-262: Proteasome and Muscle Proteostasis
2026-10-06
MG-262, also known as Z-Leu-Leu-Leu-B(OH)2, is described as a reversible, cell-permeable inhibitor of proteasome chymotryptic activity. It is a useful conceptual perturbation tool for proteasome inhibition assays, apoptosis research, and proteostasis studies, but it should not be treated as a direct inhibitor or activator of chaperone-mediated autophagy.
-
D-Luciferin Sodium Salt in CAR-Macrophage Research
2026-10-05
D-Luciferin sodium salt is a firefly luciferase substrate used for ATP-dependent bioluminescence readouts. This overview explains its evidentiary value, conceptual relevance to CAR-macrophage studies, and important limits—especially why the supplied Gu et al. paper does not establish that luciferin imaging was used in its reported experiments.
-
How Fasting Rewires Translation and Tumor Metabolism
2026-10-05
Yang et al. report that fasting suppresses global liver translation while selectively increasing translation of mRNAs required for fatty-acid catabolism and ketone-body production. The study identifies an AMPK–MNK–P-eIF4E pathway that connects elevated fatty acids to translational control and suggests a diet–drug strategy for pancreatic cancer, while leaving important questions about human applicability and fatty-acid specificity.
-
Protease Inhibitor Cocktail: Preserving Protein State
2026-10-04
Discover how a Protease Inhibitor Cocktail can support protein degradation prevention while preserving biologically meaningful sample states for proteomics. This article connects MS-compatible inhibitor design with structural insights from recent Lassa virus spike research, while clarifying evidence boundaries and interpretation limits.
-
MK-571 (L-660,711): Mechanism and Evidence
2026-10-03
MK-571, also called L-660,711, is a selective cysteinyl leukotriene receptor 1 antagonist with reported nanomolar affinity and activity in airway smooth-muscle models. Its reported MRP1 activity creates an important interpretation boundary for leukotriene-mediated inflammation research because receptor blockade and transporter inhibition are biologically distinct effects.
-
Lisinopril Dihydrate for ACE Inhibitor Studies
2026-10-02
Build reproducible ACE inhibition assays with a water-compatible, nanomolar benchmark compound. This guide connects lisinopril dihydrate handling to hypertension research, heart failure research, renal models, and peptidase-selectivity controls.
-
Lyso-Tracker Red for Lysosomal Stress Imaging
2026-10-01
Lyso-Tracker Red enables selective live-cell visualization of acidic lysosomes while helping researchers distinguish organelle remodeling from lysosomal membrane permeability. This article connects probe behavior with mechanistic insights from renal cancer research and provides an assay-design framework for interpreting lysosomal stress.
-
FerroOrange for Live-Cell Fe²⁺ Detection
2026-10-01
FerroOrange converts intracellular ferrous-ion changes into a live-cell fluorescence readout suited to microscopy, flow cytometry, and plate-based screening. This guide translates recent macrophage ferroptosis findings into a practical Fe²⁺ assay workflow while separating published evidence from optimization recommendations.
-
DCFH-DA for Mechanistic ROS Phenotyping
2026-09-30
Learn how 2,7-Dichlorodihydrofluorescein diacetate, or DCFH-DA, can support mechanistic ROS phenotyping rather than serve as a standalone oxidative-stress verdict. This guide connects probe chemistry with the layered experimental logic demonstrated in a granulosa-cell model of oxidative injury.
-
Sodium Oxamate: LDH-A Workflows for Metabolism
2026-09-30
Sodium Oxamate provides a water-soluble way to test how LDH-A-dependent lactate production shapes glycolytic phenotypes, especially in cancer models. Its value extends beyond simple growth inhibition: the reference study shows that blocking lactate-linked metabolism can produce tissue-specific effects in post-hemorrhagic brain injury, making orthogonal readouts essential.
-
Recombinant Human FGF10 in CAR-M Assays
2026-09-29
Recombinant Human FGF10 can serve as a controlled epithelial-state variable in organoid–macrophage experiments. This article explains how to use PH2040 alongside CAR-M models without confusing epithelial growth-factor effects with macrophage engineering outcomes.